Last reviewed · How we verify
Besifovir dipivoxil
Besifovir dipivoxil is a Nucleotide reverse transcriptase inhibitor Small molecule drug developed by IlDong Pharmaceutical Co Ltd. It is currently FDA-approved for Chronic hepatitis B infection. Also known as: Besivo tab.
Besifovir dipivoxil is a nucleotide reverse transcriptase inhibitor that blocks hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme.
Besifovir dipivoxil is a nucleotide reverse transcriptase inhibitor that blocks hepatitis B virus replication by inhibiting the viral reverse transcriptase enzyme. Used for Chronic hepatitis B infection.
At a glance
| Generic name | Besifovir dipivoxil |
|---|---|
| Also known as | Besivo tab |
| Sponsor | IlDong Pharmaceutical Co Ltd |
| Drug class | Nucleotide reverse transcriptase inhibitor |
| Target | Hepatitis B virus reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
Besifovir is a prodrug that is converted to besifovir in vivo, where it acts as a nucleotide analog inhibitor of hepatitis B virus (HBV) reverse transcriptase. By incorporating into the growing viral DNA chain, it causes chain termination and prevents viral replication. It has demonstrated activity against both wild-type HBV and lamivudine-resistant strains.
Approved indications
- Chronic hepatitis B infection
Common side effects
- Elevated creatinine / renal impairment
- Headache
- Fatigue
- Abdominal pain
Key clinical trials
- Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function (PHASE1)
- Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate (PHASE4)
- A Food Effect Study of Besifovir in Healthy Subjects (PHASE4)
- Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Besifovir dipivoxil CI brief — competitive landscape report
- Besifovir dipivoxil updates RSS · CI watch RSS
- IlDong Pharmaceutical Co Ltd portfolio CI
Frequently asked questions about Besifovir dipivoxil
What is Besifovir dipivoxil?
How does Besifovir dipivoxil work?
What is Besifovir dipivoxil used for?
Who makes Besifovir dipivoxil?
Is Besifovir dipivoxil also known as anything else?
What drug class is Besifovir dipivoxil in?
What development phase is Besifovir dipivoxil in?
What are the side effects of Besifovir dipivoxil?
What does Besifovir dipivoxil target?
Related
- Drug class: All Nucleotide reverse transcriptase inhibitor drugs
- Target: All drugs targeting Hepatitis B virus reverse transcriptase
- Manufacturer: IlDong Pharmaceutical Co Ltd — full pipeline
- Therapeutic area: All drugs in Virology / Hepatology
- Indication: Drugs for Chronic hepatitis B infection
- Also known as: Besivo tab